NASDAQ:ERNA Ernexa Therapeutics Q2 2024 Earnings Report $6.42 -0.70 (-9.83%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$6.50 +0.08 (+1.17%) As of 07/17/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Ernexa Therapeutics EPS ResultsActual EPS-$382.50Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AErnexa Therapeutics Revenue ResultsActual Revenue$0.05 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AErnexa Therapeutics Announcement DetailsQuarterQ2 2024Date8/13/2024TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsErnexa Therapeutics' next earnings date is estimated for Wednesday, August 12, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Ernexa Therapeutics Earnings HeadlinesErnexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA)July 15 at 12:22 PM | msn.comErnexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical EntryJuly 15 at 8:00 AM | globenewswire.comElon’s message for AmericaElon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million Americans watched, but Whitney Tilson, former manager of a $200 million hedge fund, says most investors missed what it actually means. With 1 in 3 Super Bowl viewers using buy-now-pay-later services and 40% of Americans carrying more credit card debt than savings, Tilson believes Elon's message reveals a major economic current - and a clear signal for where smart money should be positioned.July 18 at 1:00 AM | Stansberry Research (Ad)Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026July 14, 2026 | globenewswire.comEterna Therapeutics Updates Investor Presentation, Highlights Web DisclosuresJuly 2, 2026 | tipranks.comEterna Therapeutics Holds 2026 Annual Stockholder MeetingJuly 2, 2026 | tipranks.comSee More Ernexa Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ernexa Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ernexa Therapeutics and other key companies, straight to your email. Email Address About Ernexa TherapeuticsEterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.View Ernexa Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles TSMC Just Gave AI Chip Bulls Another Reason to Stay ConfidentAehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue GrowthGE Aerospace Faces a Prove-It Moment in Q2 EarningsWhy Abbott Laboratories Stock Is Suddenly Winning Back Wall StreetJ.B. Hunt Stock Could Reach $340 as Trucking Capacity ShrinksPalantir's Wild Ride: Inside the Stock Wall Street Can't Agree OnRevving Up Returns: Big Banks Race Through the Rate Plateau Upcoming Earnings General Motors (7/21/2026)Northrop Grumman (7/21/2026)America Movil (7/21/2026)Alphabet (7/21/2026)Chubb (7/21/2026)Capital One Financial (7/21/2026)Interactive Brokers Group (7/21/2026)Charles Schwab (7/21/2026)Danaher (7/21/2026)Novartis (7/21/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
